Genmab and seagen announce that tivdak® (tisotumab vedotin-tftv) met its primary endpoint of improved overall survival in patients with recurrent or metastatic cervical cancer compared to chemotherapy

Copenhagen, denmark & bothell, wash.--(business wire)--genmab a/s (nasdaq: gmab) and seagen inc. (nasdaq: sgen) announced today that the phase 3 innovatv 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received tivdak® (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (os). an independent data monitoring committee determined that os crossed the pre-specified ef.
SGEN Ratings Summary
SGEN Quant Ranking